EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Stanley Higgins Associate Vice President Nasdaq Listing Qualifications By Electronic Delivery to: karkus@prophaselabs.com December 29, 2025 Ted Karkus Principal Executive Officer ProPhase Labs, Inc. 626 RXR Plaza 6th Floor Uniondale, New York 11556 Re: ProPhase Labs, Inc. (the “Company”) – Staff Determination Nasdaq Symbol: PRPH Dear Ted Karkus: As you are aware, on December 26, 2024, Staff notified the Company that the bid price of its listed securities had closed at less than $1 per share over the previous 30 consecutive business days, and, as a result, did not comply with Listing Rule 5550(a)(2). Therefore, in accordance with Listing Rule 5810(c)(3)(A), the Company was provided 180 calendar days, or until June 24, 2025, to regain compliance with the Rule. Subsequently, on June 25, 2025, the Company was provided an additional 180 calendar day compliance period, or until December 22, 2025, to demonstrate compliance. The Company has not regained compliance with Listing Rule 5550(a)(2). Accordingly, its securities will be delisted from the Capital Market. In that regard, trading of the Compan…
Open exhibit ↗Current Report · Items 3.01, 9.01 · 8-K
ProPhase Labs, Inc.
PRPHOTCEQUITYCurrent
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.01 – Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On December 29, 2025, ProPhase Labs, Inc. (the “Company”) received a letter from the staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company did not regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share.…
Company context
We are a next-generation biotech, genomics and consumer products company. We are also focused on licensing, developing and commercializing novel drugs, dietary supplements, compounds, and diagnostics.
Current securities
Disclosure sections
Item 3.01Item 3.01 - Notice of Delisting
Item
3.01 – Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On
December 29, 2025, ProPhase Labs, Inc. (the “Company”) received a letter from the staff of The Nasdaq Stock Market LLC (“Nasdaq”)
indicating that the Company did not regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00
per share.
As
previously disclosed, the Company was provided an initial 180-day compliance period, followed by an additional 180-day compliance period,
to regain compliance with the minimum bid price requirement, which expired on December 22, 2025.
Nasdaq
indicated that trading of the Company’s common stock will be suspended at the opening of business on January 5, 2026, and that
Nasdaq will file a Form 25 with the Securities and Exchange Commission to remove the Company’s securities from listing and registration
on The Nasdaq Stock Market.
The
Company intends to timely request a hearing before the Nasdaq Hearings Panel to appeal the staff determination.
In
connection with the suspension of trading on Nasdaq, the Company is currently applying for quotation of its common stock on the OTC Markets.